Anti-tumor effects of quercetin and isoliquiritigenin in xenograft NOD/SCID mice bearing EBV(+) or EBV(−) human gastric carcinoma (SNU719 or MKN74) NOD/SCID mice were randomly divided into two groups. One group was implanted with EBV(+) human gastric carcinoma, SNU719, and the other group was implanted with EBV(−) human gastric carcinoma, MKN74. These two groups were then subdivided into three subgroups (n = 5/subgroup). Two weeks after implantation, mice were orally administrated (in drinking water) quercetin (QC, 30 mg/kg/day) or isoliquiritigenin (ISL, 30 mg/kg/day). (A) The structures of quercetin and isoliquiritigenin; (B) The study design of the animal experiment; (C) Tumor sizes in animals injected with EBV(+) positive carcinoma (SNU719) or (D) EBV(−) carcinoma (MKN74).